Drug Information

Drug (ID: DG01834) and It's Reported Resistant Information

• Name: Erastin
• Synonyms: ERASTIN; 571203-78-6; 2-[1-[4-[2-(4-chlorophenoxy)acetyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-4(3H)-Quinazolinone; 2-(1-(4-(2-(4-chlorophenoxy)acetyl)piperazin-1-yl)ethyl)-3-(2-ethoxyphenyl)quinazolin-4(3H)-one; MFCD09837984; 2-[1-[4-[2-(4-chlorophenoxy)acetyl]piperazin-1-yl]ethyl]-3-(2-ethoxyphenyl)quinazolin-4-one; CHEMBL401989; SCHEMBL4457820; Erastin, >=98% (HPLC); CHEBI:94287; AOB6043; DTXSID80458949; EX-A295; HMS3653K21; HMS3868M03; BCP27907; WXA20378; 2400AH; BDBM50376126; s7242; AKOS025147365; CCG-269987; CS-1675; Erastin - CAS 571203-78-6; SB19588; NCGC00351608-10; NCGC00351608-14; AS-55898; DA-42059; HY-15763; QC-11375; FT-0700333; SW208651-2; C21478; A869751; BRD-A25004090-001-01-9; BRD-A25004090-001-02-7; BRD-A25004090-001-06-8; Q27166099; 2-[1-[4-[2-(4-chlorophenoxy)-1-oxoethyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-4-quinazolinone; 4(3H)-Quinazolinone, 2-[1-[4-[2-(4-chlorophenoxy)acetyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Liver cancer [ICD-11: 2C12]; [1]
• Target: Sigma intracellular receptor 2 (TMEM97); SGMR2_HUMAN; [1]
• Formula: 8
• IsoSMILES: CCOC1=CC=CC=C1N2C(=O)C3=CC=CC=C3N=C2C(C)N4CCN(CC4)C(=O)COC5=CC=C(C=C5)Cl
• InChI: InChI=1S/C30H31ClN4O4/c1-3-38-27-11-7-6-10-26(27)35-29(32-25-9-5-4-8-24(25)30(35)37)21(2)33-16-18-34(19-17-33)28(36)20-39-23-14-12-22(31)13-15-23/h4-15,21H,3,16-20H2,1-2H3
• InChIKey: BKQFRNYHFIQEKN-UHFFFAOYSA-N
• PubChem CID: 11214940
• ChEBI ID: CHEBI:94287

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Liver cancer [ICD-11: 2C12]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: GABPB1 antisense RNA 1 (GABPB1-AS1) [1]

• Molecule Alteration: Down-regulation; Interaction
• Resistant Disease: Cholangiocarcinoma [ICD-11: 2C12.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: HepG2 cells; Liver; Homo sapiens (Human); CVCL_0027
• In Vitro Model: Hep3B cells; Liver; Homo sapiens (Human); CVCL_0326
• In Vitro Model: Huh7 cells; Kidney; Homo sapiens (Human); CVCL_U442
• Experiment for Drug Resistance: CCK8 assay
• Mechanism Description: LncRNA GABPB1-AS1 and GABPB1 regulate oxidative stress during erastin-induced ferroptosis in HepG2 hepatocellular carcinoma cells.

References

• Ref 1: LncRNA GABPB1-AS1 and GABPB1 regulate oxidative stress during erastin-induced ferroptosis in HepG2 hepatocellular carcinoma cellsSci Rep. 2019 Nov 7;9(1):16185. doi: 10.1038/s41598-019-52837-8.